Health News (Reuters)

Big pharma, big data: why drugmakers want your health records

LONDON (Reuters) - Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world.

Mylan teams up with Revance on biosimilar for Botox

NEW YORK (Reuters) - Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.

Firearm-related injuries drop during NRA conventions

(Reuters Health) - Gunshot-related deaths and injuries temporarily show a dramatic decline when the National Rifle Association is holding its annual convention, according to a new analysis in the New England Journal of Medicine.

Vaping may help pneumonia-causing bacteria invade airways

(Reuters Health) - People who smoke e-cigarettes might have an increased risk of developing pneumonia because the vapor could help bacteria stick to cells lining the airways, a small experiment suggests.

Doctor admits disclosing patient info to drugmaker Aegerion

BOSTON (Reuters) - A Georgia pediatric cardiologist pleaded guilty on Wednesday to wrongfully disclosing information about his young patients to an Aegerion Pharmaceuticals Inc sales representative seeking to identify potential new users of an expensive cholesterol drug.

Another reason to worry about overcrowded emergency rooms

(Reuters Health) - Patients are more likely to be misdiagnosed or experience treatment delays when emergency rooms are so crowded that they receive care in a hallway, a survey of physicians suggests.

Coca-Cola defeats U.S. lawsuit over Diet Coke ads

(Reuters) - A federal judge has dismissed a lawsuit claiming that Coca-Cola Co's advertising for Diet Coke misleads people into thinking that consuming the soft drink assists in weight loss, and that it actually causes weight gain.

Netherlands confirms highly pathogenic H5N6 bird flu outbreak

PARIS (Reuters) - The Netherlands confirmed an outbreak of highly pathogenic H5N6 bird flu at a farm in the northern part of the country, the World Organisation for Animal Health (OIE) said on Wednesday, citing a report from the Dutch ministry of Economic Affairs.

Yes, working hard in high school can pay off later

(Reuters Health) - High school students who are responsible and have solid reading and writing skills may be more likely to succeed in college and go on to snag a high-paying, prestigious job than their classmates who slack off, a new study confirms.

Europe follows FDA with plans to help early Alzheimer's drugs

LONDON (Reuters) - European regulators are following in the footsteps of the U.S. Food and Drug Administration with plans to help pharmaceutical companies win approval for novel Alzheimer's drugs that treat the earliest stages of the memory-robbing disease.

Mississippi moves closer to banning abortions after 15 weeks

(Reuters) - Mississippi moved a step closer on Tuesday to passing the United States' most restrictive abortion law when a state Senate committee approved a bill banning most procedures after 15 weeks of gestation.

U.S. subpoenas Mallinckrodt for information on opioid painkillers

(Reuters) - Pharmaceutical company Mallinckrodt Plc said on Tuesday it had received a grand jury subpoena from federal prosecutors in Florida seeking documents related to generic drugs it produces that contain the opioid painkiller oxymorphone.

U.S. to seek reimbursement from opioid makers, distributors

WASHINGTON (Reuters) - The federal government, backing litigation by states and cities, will seek reimbursement from major drug companies and distributors to recover costs it has borne from the opioid epidemic, the U.S. Justice Department said on Tuesday.

U.S. FDA rejects filing for Celgene MS drug, shares fall

(Reuters) - U.S. health regulators have rejected Celgene Corp's application seeking approval of a key multiple sclerosis drug due to insufficient data, the company said on Tuesday, a surprise development that will likely delay the entry to market of one of Celgene's most important pipeline assets.

Pages